Temozolomide, Simvastatin and Acetylshikonin Combination Induces Mitochondrial-Dependent Apoptosis in GBM Cells, Which Is Regulated by Autophagy
Author:
Hajiahmadi Sima1, Lorzadeh Shahrokh2ORCID, Iranpour Rosa2, Karima Saeed1, Rajabibazl Masoumeh1, Shahsavari Zahra1ORCID, Ghavami Saeid234ORCID
Affiliation:
1. Department of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran 2. Department of Human Anatomy and Cell Science, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0V9, Canada 3. Faculty of Medicine in Zabrze, Academia of Silesia, 41-800 Zabrze, Poland 4. Research Institute of Oncology and Hematology, Cancer Care Manitoba, University of Manitoba, Winnipeg, MB R3T 2N2, Canada
Abstract
Glioblastoma multiforme (GBM) is one of the deadliest cancers. Temozolomide (TMZ) is the most common chemotherapy used for GBM patients. Recently, combination chemotherapy strategies have had more effective antitumor effects and focus on slowing down the development of chemotherapy resistance. A combination of TMZ and cholesterol-lowering medications (statins) is currently under investigation in in vivo and clinical trials. In our current investigation, we have used a triple-combination therapy of TMZ, Simvastatin (Simva), and acetylshikonin, and investigated its apoptotic mechanism in GBM cell lines (U87 and U251). We used viability, apoptosis, reactive oxygen species, mitochondrial membrane potential (MMP), caspase-3/-7, acridine orange (AO) and immunoblotting autophagy assays. Our results showed that a TMZ/Simva/ASH combination therapy induced significantly more apoptosis compared to TMZ, Simva, ASH, and TMZ/Simva treatments in GBM cells. Apoptosis via TMZ/Simva/ASH treatment induced mitochondrial damage (increase of ROS, decrease of MMP) and caspase-3/7 activation in both GBM cell lines. Compared to all single treatments and the TMZ/Simva treatment, TMZ/Simva/ASH significantly increased positive acidic vacuole organelles. We further confirmed that the increase of AVOs during the TMZ/Simva/ASH treatment was due to the partial inhibition of autophagy flux (accumulation of LC3β-II and a decrease in p62 degradation) in GBM cells. Our investigation also showed that TMZ/Simva/ASH-induced cell death was depended on autophagy flux, as further inhibition of autophagy flux increased TMZ/Simva/ASH-induced cell death in GBM cells. Finally, our results showed that TMZ/Simva/ASH treatment potentially depends on an increase of Bax expression in GBM cells. Our current investigation might open new avenues for a more effective treatment of GBM, but further investigations are required for a better identification of the mechanisms.
Funder
UCRP operating University of Manitoba undergraduate award
Subject
General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology
Reference87 articles.
1. Targeting cholesterol metabolism in glioblastoma: A new therapeutic approach in cancer therapy;Pirmoradi;J. Investig. Med.,2019 2. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide;Johannessen;Int. J. Cancer,2019 3. Grochans, S., Cybulska, A.M., Simińska, D., Korbecki, J., Kojder, K., Chlubek, D., and Baranowska-Bosiacka, I. (2022). Epidemiology of Glioblastoma Multiforme–Literature Review. Cancers, 14. 4. Recent advances on glioblastoma multiforme and nano-drug carriers: A review;Liao;Curr. Med. Chem.,2019 5. Cruz, J.V.R., Batista, C., Afonso, B.d.H., Alexandre-Moreira, M.S., Dubois, L.G., Pontes, B., Moura Neto, V., and Mendes, F.d.A. (2022). Obstacles to glioblastoma treatment two decades after temozolomide. Cancers, 14.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|